Navigation Links
Treating drug resistant cancer through targeted inhibition of sphingosine kinase
Date:8/9/2012

Scientists at Tulane University School of Medicine, led by Dr. James Antoon and Dr. Barbara Beckman, have characterized two drugs targeting sphingosine kinase (SK), an enzyme involved in cancer growth and metastasis. New treatments specifically attacking cancer cells, but not normal ones, are critical in the fight against cancer. The results, which appear in the July 2012 issue of Experimental Biology and Medicine, demonstrate the role of SK in drug resistance and therapeutic potential of SK inhibitors.

"Sphingosine kinase is a relatively new molecular target," says Dr. Beckman "In this study, we show that overexpression of SK promotes resistance to first-line breast cancer therapies, such as tamoxifen. We further found that treatment with the sphingosine kinase inhibitors SKI-II and ABC294640 induced cell death and blocked drug-resistant tumor growth without similar effects in a model system representing relatively normal breast cells."

Molecular therapies, such as those targeting SK, have the potential to improve treatment response rates while simultaneously decreasing side effects. However, Dr. Antoon cautions that "while these results are promising, further study is needed to fully understand the benefits and risks associated with treating drug resistant cancer with these SK inhibitors."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Dr. Antoon, Dr. Beckman and colleagues present exciting results indicating the need for further study of inhibitors of sphingosine kinase as promising new cancer treatments".


'/>"/>
Contact: Dr. James Antoon
jantoon@tulane.edu
Society for Experimental Biology and Medicine
Source:Eurekalert

Page: 1

Related medicine news :

1. Study Suggests Treating Dyslexia Before Kids Learn to Read
2. New standards for treating traumatic shoulder injuries to improve patient care
3. Treating childhood obesity: A family affair
4. Unique physiology key to diagnosing and treating diabetes in Asian populations
5. Studies See Advances in Detecting, Treating Pancreatic Cancer
6. 1 size doesnt fit all when treating blood pressure in people with diabetes, VA/U-M study suggests
7. Nanomedicines promise fewer side effects in treating cancer
8. Mount Sinai researchers develop a multi-target approach to treating tumors
9. A non-antibiotic approach for treating urinary tract infections
10. UT Southwestern study shows treating diabetes early, intensively is best strategy
11. Researchers report success in treating autism spectrum disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: